Compositions and methods for the treatment of cancer

Abstract

The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII and formula VIII and, the methods for the treatment of cancer and infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of cancer, neoplasm, infections and skin diseases.

1 . A compound of formula I: 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof; wherein
 R 1 , R 3  represents CD 3 , CD 2 , H, D, O, OD, CD 3 CO, NULL, 
 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         R 2 , R 4  independently represents 
       
       
         
           
           
               
               
           
         
       
       within the proviso, wherein
 n represents 0 to 12; 
 R 5  and R 6  independently represents 
 
       
         
           
           
               
               
           
         
       
     
     
         2 . (canceled) 
     
     
         3 . A compound of formula III: 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof; wherein
 R 1 , R 3 , R 5  represents CD 3 , CD 2 , H, D, O, OD, CD 3 CO, NULL, 
 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         R 2 , R 4  independently represents 
       
       
         
           
           
               
               
           
         
         within the proviso, wherein 
         n represents 0 to 12; 
         R 6  independently represents NULL, 
       
       
         
           
           
               
               
           
         
       
     
     
         4 .- 7 . (canceled) 
     
     
         8 . A compound of formula VIII: 
       
         
           
           
               
               
           
         
       
       and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof; wherein
 R 1  represents CD 3 , CD 2 , H, D, O, OD, CD 3 CO, NULL, 
 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         R 2  independently represents 
       
       
         
           
           
               
               
           
         
         within the proviso, 
         wherein 
         n represents 0 to 12; 
         R 5  and R 6  independently represent: 
       
       
         
           
           
               
               
           
         
       
     
     
         9 . A pharmaceutical composition comprising a compound of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         10 . (canceled) 
     
     
         11 . A pharmaceutical composition comprising a compound of  claim 3  and a pharmaceutically acceptable carrier. 
     
     
         12 .- 15 . (canceled) 
     
     
         16 . A pharmaceutical composition comprising a compound of  claim 8  and a pharmaceutically acceptable carrier. 
     
     
         17 . The pharmaceutical composition of  claim 9 , wherein said pharmaceutical composition is formulated to treat an underlying etiology in a patient in need by administering an effective amount of said pharmaceutical composition to the patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. 
     
     
         18 . (canceled) 
     
     
         19 . The pharmaceutical composition of  claim 11 , wherein said pharmaceutical composition is formulated to treat an underlying etiology in a patient in need by administration an effective amount of said pharmaceutical composition to the patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. 
     
     
         20 .- 23 . (canceled) 
     
     
         21 . The pharmaceutical composition of  claim 16 , wherein said pharmaceutical composition is formulated to treat an underlying etiology in a patient in need by administering an effective amount of said pharmaceutical composition to the patient in need by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. 
     
     
         24 . The pharmaceutical composition of  claim 17 , wherein said pharmaceutical composition is formulated for the treatment of colorectal cancer, breast cancer, gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers, head and neck cancers, actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis or oral infectious diseases. 
     
     
         25 . (canceled) 
     
     
         26 . The pharmaceutical composition of  claim 19 , wherein said pharmaceutical composition is formulated for the treatment of colorectal cancer, breast cancer, gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers, head and neck cancers, actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis or oral infectious diseases. 
     
     
         27 .- 31 . (canceled) 
     
     
         32 . The pharmaceutical composition of  claim 24 , wherein said pharmaceutical composition is formulated for the treatment of colorectal cancer, breast cancer, gastric cancer, oesophageal cancer, anal, breast, colorectal, oesophageal, stomach, pancreatic and skin cancers, head and neck cancers, actinic keratoses, skin cancers, Bowen's disease, fungal infections, candidiasis or infectious diseases.